Mortality rates for pneumonia and pulmonary fibrosis have declined since 1999, but disparities persist by sex, race, and region. The COVID-19 pandemic caused a temporary spike in mortality rates, ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Please provide your email address to receive an email when new articles are posted on . High oral microbial diversity in IPF is linked to decreased lung function and an elevated mortality risk.

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Patients with idiopathic pulmonary fibrosis and CKD have limited options for antifibrotic therapy. Mortality risk appears no higher for patients with chronic kidney disease (CKD) and idiopathic ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

Please provide your email address to receive an email when new articles are posted on . Frailty was measured via the Survey of Health, Aging and Retirement in Europe-Frailty Instrument. No correlation ...

MONTGOMERY COUNTY, Texas (KTRK) -- On a sunny and crisp fall day in Montgomery County, Arturo "Hito" Bazan remembers his darkest days. "Nothing really matters when you can't breathe. When you can't ...

Last year, Houghton Hutcheson, now 79, started experiencing shortness of breath on a trip to Colorado. When he returned, he scheduled a visit with his primary care physician, Eric Thomas, MD, MPH, ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...